Cocrystal Pharma, Inc. (COCP) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Cocrystal Pharma, Inc. (COCP) Healthcare & Pipeline Overview

Cocrystal Pharma, Inc. is a biotechnology firm specializing in structure-based antiviral drug discovery for diseases like hepatitis C, influenza, coronavirus, and norovirus. Their pipeline includes Phase II clinical trials for HCV treatments and preclinical development for influenza, positioning them in the competitive antiviral therapeutics market.

What Is the Investment Thesis for COCP?

Cocrystal Pharma presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The company's focus on structure-based drug design offers a potentially differentiated approach to antiviral therapeutics. Successful development and commercialization of CC-31244 for HCV or CC-42344 for influenza could drive significant value. The collaborations with Merck and Kansas State University provide validation and potential revenue streams. However, the company's negative profit margin of -3924.0% and small market cap of $9.53M highlight the financial risks. Investors should closely monitor clinical trial results, partnership developments, and cash burn rate.

Based on FMP financials and quantitative analysis

COCP Key Highlights

• Market Cap of $9.53M indicates a micro-cap company with high growth potential but also significant risk.
• Gross Margin of 669.8% suggests strong pricing power on existing revenue streams, although this may be related to specific licensing agreements or research grants rather than product sales.
• Profit Margin of -3924.0% reflects substantial ongoing R&D expenses typical of biotechnology companies in the drug development phase.
• Beta of 1.50 indicates higher volatility compared to the overall market, reflecting the speculative nature of biotechnology stocks.
• Focus on antiviral therapeutics targeting diseases like HCV, influenza, coronavirus, and norovirus positions the company in areas of significant unmet medical need and potential market opportunity.

Who Are COCP's Competitors?

COCP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are COCP's Key Strengths?

• Proprietary structure-based drug design technology.
• Focus on high-need antiviral targets.
• Strategic collaborations with Merck and Kansas State University.
• CC-31244 has completed Phase II a clinical trial.

What Are COCP's Weaknesses?

• Limited financial resources.
• Small number of employees.
• Dependence on partnerships for late-stage development and commercialization.
• High risk of clinical trial failure.

What Could Drive COCP Stock Higher?

• Announcement of results from ongoing preclinical studies for CC-42344 (influenza).
• Potential new partnerships or licensing agreements for antiviral programs.
• Continued research and development efforts in norovirus and coronavirus therapeutics.
• Advancing CC-31244 through clinical development stages.

What Are the Key Risks for COCP?

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for drug candidates.
• Competition from larger pharmaceutical companies with greater resources.
• Regulatory delays or rejection of drug applications.
• Dependence on external funding and partnerships.
• Patent challenges and intellectual property disputes.

What Are the Growth Opportunities for COCP?

• Advancement of CC-31244 for HCV: Cocrystal Pharma's CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial, represents a significant near-term growth opportunity. Successful completion of Phase III trials and subsequent regulatory approval could lead to a substantial revenue stream. The global market for HCV therapeutics is estimated to be billions of dollars, although competition is intense. Timeline: 2-3 years for potential market entry, pending trial outcomes.
• Development of CC-42344 for Influenza: The preclinical development of CC-42344, a PB2 inhibitor for treating influenza infection, offers a longer-term growth opportunity. Influenza remains a major public health concern, and new antiviral agents are needed to combat drug-resistant strains. The influenza therapeutics market is substantial, with annual sales in the billions. Timeline: 3-5 years for potential market entry, pending preclinical and clinical trial results.
• Expansion of Norovirus Program: Cocrystal Pharma's efforts to identify and develop non-nucleoside polymerase inhibitors for norovirus infections represent a significant growth opportunity. Norovirus is a leading cause of gastroenteritis worldwide, and there are currently no approved antiviral treatments. Successful development of a norovirus therapeutic could capture a significant share of this unmet market. Timeline: 4-6 years for potential market entry, pending preclinical and clinical trial results.
• Strategic Partnerships and Licensing Agreements: Cocrystal Pharma's existing collaborations with Merck and Kansas State University provide a foundation for future partnerships and licensing agreements. These collaborations can provide funding, expertise, and access to new technologies, accelerating the development of antiviral therapeutics. Securing additional partnerships could significantly enhance Cocrystal Pharma's growth prospects. Timeline: Ongoing.
• Expansion into Coronavirus Therapeutics: Given the ongoing threat of coronaviruses, including SARS-CoV-2 variants, Cocrystal Pharma's expertise in structure-based drug design could be leveraged to develop novel coronavirus therapeutics. This represents a significant growth opportunity, as the market for coronavirus treatments is expected to remain substantial in the coming years. Timeline: 3-5 years for potential market entry, pending preclinical and clinical trial results.

What Opportunities Does COCP Have?

• Expanding into new antiviral targets, such as coronavirus.
• Securing additional partnerships and licensing agreements.
• Advancing CC-31244 through Phase III trials and regulatory approval.
• Developing novel antiviral agents for norovirus infections.

What Threats Does COCP Face?

• Competition from larger pharmaceutical companies.
• Patent expiration and generic competition.
• Regulatory hurdles and delays.
• Clinical trial failures.

What Are COCP's Competitive Advantages?

• Proprietary structure-based drug design technology.
• Patent protection on novel antiviral compounds.
• Strategic collaborations with leading pharmaceutical companies and research institutions.
• Expertise in targeting specific viral enzymes, such as polymerase inhibitors.

What Does COCP Do?

Cocrystal Pharma, Inc., founded to combat serious and chronic viral diseases, operates as a biotechnology company focused on the discovery and development of innovative antiviral therapeutic treatments. The company leverages structure-based technologies to design antiviral drugs, primarily targeting hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. Their approach involves understanding the molecular structure of viruses to create effective inhibitors. Cocrystal Pharma's pipeline includes CC-31244, a HCV non-nucleoside polymerase inhibitor, which has completed Phase II a clinical trial for treating HCV infection. Additionally, CC-42344, a PB2 inhibitor, is in preclinical development trials for treating influenza infection. The company is also actively involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections, addressing a significant unmet medical need. Strategic collaborations are a key component of Cocrystal Pharma's business model. They have a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents. Additionally, they hold a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. They also engage in drug discovery collaboration with HitGen and InterX Inc. Headquartered in Bothell, Washington, Cocrystal Pharma continues to advance its research and development efforts in the antiviral space.

What Products and Services Does COCP Offer?

• Discovers and develops antiviral therapeutic treatments.
• Focuses on serious and/or chronic viral diseases.
• Employs structure-based technologies to create antiviral drugs.
• Targets hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.
• Develops non-nucleoside polymerase inhibitors.
• Conducts preclinical and clinical trials to evaluate drug candidates.

How Does COCP Make Money?

• Develops antiviral drug candidates through internal research and development.
• Out-licenses or partners with larger pharmaceutical companies for late-stage development and commercialization.
• Generates revenue through licensing fees, milestone payments, and royalties on sales of approved drugs.
• Collaborates with research institutions and other companies to access new technologies and expertise.

What Industry Does COCP Operate In?

Cocrystal Pharma operates within the highly competitive biotechnology industry, specifically targeting the antiviral therapeutics market. This market is characterized by intense research and development, stringent regulatory requirements, and a constant need for innovation to address evolving viral strains and resistance. The competitive landscape includes large pharmaceutical companies like Gilead Sciences and Roche, as well as smaller biotech firms focused on specific antiviral targets. The antiviral drug market is projected to grow, driven by increasing prevalence of viral infections and advancements in drug development technologies.

Who Are COCP's Key Customers?

• Larger pharmaceutical companies seeking to expand their antiviral drug portfolios.
• Patients suffering from viral infections, such as HCV, influenza, coronavirus, and norovirus.
• Healthcare providers who prescribe antiviral medications.
• Government agencies and public health organizations involved in combating viral outbreaks.

FY2026 estForward Outlook

Wall Street analysts project Cocrystal Pharma, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.69.

Key Financial Metrics

Its free cash flow yield is -72.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -61.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Cocrystal Pharma, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

COCP Valuation & Market Position

With a $9.53M market cap, Cocrystal Pharma, Inc. sits in the micro-cap segment of the market. Relative to its peer group, COCP's quantitative score of 18/100 is below the peer average of 75/100.

COCP Financials

COCP Latest News

COCP Analyst Consensus

COCP MoonshotScore

Cocrystal Pharma, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources